Forest agrees another license deal for Bystolic

US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement agreement with USA-based Amerigen Pharmaceuticals over a patent infringement litigation.

Forest brought the legal action in response to Amerigen's Abbreviated New Drug Application for generic versions of Forest’s antihypertensive Bystolic (nebivolol).

Under the terms of the settlement agreement, and subject to review of the settlement terms by the US Federal Trade Commission, Forest will provide a license to Amerigen that will permit it to launch its generic versions of Bystolic three calendar months prior to the expiration of its patent (scheduled for December 2021 according to Forest), including any extensions and/or pediatric exclusivities, or the date Amerigen receives final Food and Drug Administration approval of its ANDA, whichever is the later.